Ona Therapeutics SL is accelerating development of its first-in-class antibody-drug conjugate (ADC) therapeutics, targeting novel tumor-specific markers to eliminate hard-to-treat, resistant cancer ...

Some of these markers had a proven better sensitivity ... papillary superficial and solid invasive tumors. Superficial tumors are the most frequent of all newly diagnosed bladder cancers ...

Epitopea Ltd. has signed a license and research collaboration agreement with MSD (Merck & Co. Inc.) to identify Cryptigen tumor-specific antigens in an undisclosed solid tumor. Cryptigen TSAs are ...

In combination with established tumor markers, EDTA-plasma M2-PK is a useful ... melanoma and other solid tumors. Tumor M2-PK can be detected in EDTA-plasma and in the feces.

For instance, understanding the differences between early and late-stage cancers, how pervasively specific cancers spread, ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

A groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children ...

Brookline initiated coverage of Marker Therapeutics (MRKR) with a Buy rating and $4 price target Marker is a clinical-stage immuno-oncology ...

Ona Therapeutics ("Ona"), a global biotech company pioneering first-in-class antibody-drug conjugates (ADCs), today announced key leadership appointments to support its rapid growth and pipeline ...

Bolt Biotherapeutics, Inc., announced today that the target of their worldwide co-development collaboration with Toray Industries, Inc. is Caprin-1, a novel cancer target discovered by Toray. The ...